Dr. Simó Schwartz Jr, director of the CIBBIM-Nanomedicine of the Vall d’Hebron Institute of Research (VHIR), has been appointed as a member of the advisory board of the Nanomedicine Characterisation Laboratory (EU-NCL). Dr. Schwartz will collaborate with the EU-NCL defining the objectives as well as setting up the strategic plan and director plan.
The EU-NCL is an infrastructure, similar to the American Nanotechnology Characterization Laboratory, which offers services of physical and chemical characterisation of the therapeutic nanoconjugates developed by research centers, public laboratories, spin-offs and innovative enterprises.
The EU-NCL has 3 members in their external advisory board, among which we can find Dr. Schwartz, and 9 European partners who met for the first time in May in Trondheim, Norway. In the meeting, they reviewed the projects and the work carried out up to date and they set up the collaboration objectives for the financing of new studies.
Image: Dr. Simó Schwartz Jr
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
